On August 17, 2025, PharmaCyte Biotech, Inc. entered a Securities Purchase Agreement to sell 7,000 shares of convertible preferred stock for a total of $7 million, convertible into common stock at $1.00 per share. The funding will support general corporate purposes, with subsequent stockholder approval required by October 31, 2025.